ArticleAACE endocrinology and diabetes
Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We evaluated the effect of cognitive behavioral therapy delivered via a novel digital therapeutic application (app) on antihyperglycemic medication use in adults with type 2 diabetes. Methods: Trial participants were randomized to receive access to BT-001 or a control app for 180 days. Antihyperglycemic medications were adjusted as needed, consistent with the standard of care, and all concomitant therapies were permitted. Change in antihyperglycemic medication from the baseline to the study exit was compared between treatment groups. Results: Among 668 randomized participants, the mean number of antihyperglycemic medications at the baseline was 2 ± 1 for both groups. The increase in number or dose of medications from the baseline to the study exit was greater in the control group compared with the BT-001 group ( Conclusions: BT-001, the first prescription digital therapeutic authorized for treatment of type 2 diabetes, significantly reduced intensification of antihyperglycemic therapy compared to the control app and reduced insulin usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.